Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV(mac251) Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given the limited ability of the vaccine components to...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Pegu, Poonam, Vaccari, Monica, Gordon, Shari, Keele, Brandon F., Doster, Melvin, Guan, Yongjun, Ferrari, Guido, Pal, Ranajit, Ferrari, Maria Grazia, Whitney, Stephen, Hudacik, Lauren, Billings, Erik, Rao, Mangala, Montefiori, David, Tomaras, Georgia, Alam, S. Munir, Fenizia, Claudio, Lifson, Jeffrey D., Stablein, Donald, Tartaglia, Jim, Michael, Nelson, Kim, Jerome, Venzon, David, Franchini, Genoveffa
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society for Microbiology 2013
الموضوعات:
Vaccines and Antiviral Agents
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3554145/
https://ncbi.nlm.nih.gov/pubmed/23175374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02544-12
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة